Superluminal Medicines has raised $60 million in an oversubscribed Series B financing led by BVF Partners, L.P. New investors Deep Track Capital and Perceptive Advisors participated alongside existing investors RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels.
The Boston-based biotechnology company plans to use the financing to advance its lead program for rare genetic forms of obesity and hypothalamic obesity into clinical development. The program is a selective, biased MC4R agonist, with a Phase 1 clinical trial expected to begin by the end of 2026. The capital will also support additional pipeline programs and expansion of Superluminal’s portfolio of small-molecule therapies targeting G protein-coupled receptors, or GPCRs, for endocrine and cardiometabolic diseases.
Superluminal was co-founded by Cony D’Cruz, who serves as CEO, and Ajay Yekkirala, who leads discovery. The company combines structural biology, computational and medicinal chemistry, machine learning and experimental approaches to discover small-molecule therapeutics, with an initial focus on GPCR targets.
The Series B follows a $120 million Series A led by RA Capital Management in September 2024 and a $33 million seed financing announced in August 2023.
Superluminal also has a collaboration with Eli Lilly and Company to discover and develop small-molecule therapies targeting undisclosed GPCRs for obesity and other cardiometabolic diseases. The agreement, announced in 2025, could provide Superluminal with up to $1.3 billion through payments and development and commercial milestones, along with an equity investment and royalties. Superluminal’s lead MC4R program is separate from the Lilly collaboration.
